Get The App!
Loading the player...
Dr. Srdan Verstovsek Discusses Approval of Ruxolitinib as a New Therapy for Patients with Polycythemia Vera
Share by Email
Send to social websites
Report this video as inappropriate
You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email.
Select your reason
Violent or Repulsive Content
Hateful or Abusive Content
Harmful Dangerous Acts
At ASH 2014, Dr. Srdan Verstovsek discussed the approval of ruxolitinib as a new therapy for patients with polycythemia vera.
Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Ac...
Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or...
Introduction to the ImpactLive MPN program
Is the Rate of MPN Leukemic Transformation (ie, BP-MPN) Affected by Prior Therapy?
Are There Certain Genetic Alterations That May Help Identify Patients at Risk for Imminent Leukemic ...
For HSCT Candidates with Advancing MF, What are Their Chief Reasons for Electing Not to Undergo Tran...
Do Patients Ever Present with >5% Peripheral Blasts at Diagnosis?
If Peripheral Blasts Increase While on Ruxolitinib, is That Considered Treatment Failure?
Copyright 2020 by NSCI Group, Inc.
On The Go
About MedEd On The Go